Baropharm raises $21.4M in KOSDAQ listing after first profit
What's the deal? South Korean pharmacy platform Baropharm listed on KOSDAQ on November 11, raising US$24.5M through a public offering of new shares. The company priced at the bottom of its indicative range, selling 1.78 million shares at US$13.8 each.
What's the endgame? Founded in 2019, Baropharm runs an integrated ordering platform that lets pharmacies compare inventory and prices across wholesalers and place orders at once. It now counts 24,787 pharmacies as members — roughly 90% of all pharmacies nationwide — with cumulative order value of US$6.04B.
The numbers: Baropharm swung to profit in the first half of 2026, posting US$57.9M in revenue, up 56.2% year-on-year, and operating profit of US$1.84M. That reversed operating losses of US$2.1M in 2023, US$4.61M in 2024, and US$3.27M in 2025.
Why now? Chief executive officer Kim Seul-gi said the heavy spending is behind it. "The costs of building the platform infrastructure and securing customers were already reflected in the previous three years," she said, with all three divisions — platform, partnership distribution, and in-house brands — now growing in step.
What's the endgame, continued? Proceeds will fund AI-based pharmacy services, brand marketing, overseas expansion, and added production capacity. Baropharm is pushing its own brands abroad, confirming placement of its cosmetics line in 500 Japanese drugstores and multi-brand shops, and is preparing Amazon sales in the US.
What could go wrong? One profitable half-year does not establish durable margins. Much of Baropharm's growth comes from low-margin direct distribution, and its membership rate has already neared its ceiling. Investor reception was cautious: the deal priced at the floor, institutional demand was modest, and almost no institutions sought lockups.
The signal: Baropharm listed under KOSDAQ's "Tesla" rules, which let high-growth firms go public before proving sustained profits. Its subdued debut fits a selective IPO market where weak post-listing performance has made investors weigh demonstrated earnings over growth claims alone.
Read more: chosun.com
Image credit: Baropharm